Comparison Overview

Arch Pharmalabs, Ltd.

VS

SUN PHARMA

Arch Pharmalabs, Ltd.

"H" Wing, 4th Floor, Tex Centre, Andheri (E), Mumbai, undefined, 400 072, IN
Last Update: 2025-03-05 (UTC)

Founded in 1999,Arch Pharmalabs has gained recognition as a world-class provider of small molecule process chemistry, custom synthesis services and full life-cycle API and drug intermediates manufacture for the global pharmaceutical industry. Generating revenues of USD 200 million, our India-based offering is supported by 2,400 customer-centric Archers, eleven certified facilities (including cGMP-compliant, US FDA- and EDQM-approved sites) and two state-of-the-art Process Technology centres. Arch Pharmalabs works tirelessly to deliver value, innovation and effective supply chain solutions in the spirit of true partnership. Our large family of satisfied customers range from emerging or specialty companies to global majors, many of whom have designated Arch Pharmalabs as a Preferred Supplier or Strategic Partner. Arch Pharmalabs received CNBC TV Emerging India 2006 Award as the No.1 Small or Medium Company in the Pharmaceuticals and Chemicals category.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 678
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

SUN PHARMA

Sun House, CTS No. 201 B/1,, Mumbai, Maharastra, 400063, IN
Last Update: 2025-05-06 (UTC)
Between 800 and 849

Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 36,883
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/arch-pharmalabs-ltd..jpeg
Arch Pharmalabs, Ltd.
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/sun-pharma.jpeg
SUN PHARMA
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Arch Pharmalabs, Ltd.
100%
Compliance Rate
0/4 Standards Verified
SUN PHARMA
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Arch Pharmalabs, Ltd. in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for SUN PHARMA in 2025.

Incident History — Arch Pharmalabs, Ltd. (X = Date, Y = Severity)

Arch Pharmalabs, Ltd. cyber incidents detection timeline including parent company and subsidiaries

Incident History — SUN PHARMA (X = Date, Y = Severity)

SUN PHARMA cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/arch-pharmalabs-ltd..jpeg
Arch Pharmalabs, Ltd.
Incidents

No Incident

https://images.rankiteo.com/companyimages/sun-pharma.jpeg
SUN PHARMA
Incidents

No Incident

FAQ

SUN PHARMA company demonstrates a stronger AI Cybersecurity Score compared to Arch Pharmalabs, Ltd. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, SUN PHARMA company has disclosed a higher number of cyber incidents compared to Arch Pharmalabs, Ltd. company.

In the current year, SUN PHARMA company and Arch Pharmalabs, Ltd. company have not reported any cyber incidents.

Neither SUN PHARMA company nor Arch Pharmalabs, Ltd. company has reported experiencing a ransomware attack publicly.

Neither SUN PHARMA company nor Arch Pharmalabs, Ltd. company has reported experiencing a data breach publicly.

Neither SUN PHARMA company nor Arch Pharmalabs, Ltd. company has reported experiencing targeted cyberattacks publicly.

Neither Arch Pharmalabs, Ltd. company nor SUN PHARMA company has reported experiencing or disclosing vulnerabilities publicly.

Neither Arch Pharmalabs, Ltd. nor SUN PHARMA holds any compliance certifications.

Neither company holds any compliance certifications.

SUN PHARMA company has more subsidiaries worldwide compared to Arch Pharmalabs, Ltd. company.

SUN PHARMA company employs more people globally than Arch Pharmalabs, Ltd. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Arch Pharmalabs, Ltd. nor SUN PHARMA holds SOC 2 Type 1 certification.

Neither Arch Pharmalabs, Ltd. nor SUN PHARMA holds SOC 2 Type 2 certification.

Neither Arch Pharmalabs, Ltd. nor SUN PHARMA holds ISO 27001 certification.

Neither Arch Pharmalabs, Ltd. nor SUN PHARMA holds PCI DSS certification.

Neither Arch Pharmalabs, Ltd. nor SUN PHARMA holds HIPAA certification.

Neither Arch Pharmalabs, Ltd. nor SUN PHARMA holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

The Bold Page Builder plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the ‘percentage’ parameter in all versions up to, and including, 5.4.5 due to insufficient input sanitization and output escaping. This makes it possible for authenticated attackers, with Contributor-level access and above, to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page.

Risk Information
cvss3
Base: 6.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:C/C:L/I:L/A:N
Description

The ComboServlet in Liferay Portal 7.4.0 through 7.4.3.111, and older unsupported versions, and Liferay DXP 2023.Q4.0 through 2023.Q4.2, 2023.Q3.1 through 2023.Q3.5, 7.4 GA through update 92, 7.3 GA through update 35, and older unsupported versions does not limit the number or size of the files it will combine, which allows remote attackers to create very large responses that lead to a denial of service attack via the URL query string.

Risk Information
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and create arbitrary directories on the target machine.

Risk Information
cvss3
Base: 4.0
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:L/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A relative path traversal vulnerability was discovered in Productivity Suite software version 4.4.1.19. The vulnerability allows an unauthenticated remote attacker to interact with the ProductivityService PLC simulator and delete arbitrary files on the target machine.

Risk Information
cvss3
Base: 7.5
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:C/C:N/I:L/A:H
cvss4
Base: 8.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:P/PR:N/UI:N/VC:N/VI:L/VA:H/SC:N/SI:L/SA:L/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X